Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update).


Journal

Sexual medicine reviews
ISSN: 2050-0521
Titre abrégé: Sex Med Rev
Pays: Netherlands
ID NLM: 101614773

Informations de publication

Date de publication:
04 2021
Historique:
received: 18 09 2019
revised: 21 01 2020
accepted: 23 01 2020
pubmed: 23 3 2020
medline: 15 12 2021
entrez: 23 3 2020
Statut: ppublish

Résumé

Collagenase Clostridium histolyticum (CCH) is an injectable agent used to treat Peyronie's disease (PD) by enzymatically degrading the interstitial collagen in plaques. CCH has been administered via multiple treatment protocols, in combination therapies, to patients with varying curvatures and in both the acute and stable phases of this condition. To review the current literature and provide an update on CCH as an injectable therapy for PD, as a singular therapy or in conjunction with combination therapies, and its associated complications. We provide a brief background of PD treatments, evaluate CCH efficacy in penile curvature reduction and subjective improvement in a variety of protocols, and compare combination therapies (penile traction, sildenafil), plaque location, and efficacy in both acute and stable diseases. We performed a systematic review of the existing PubMed literature pertaining to CCH injection therapy in the treatment of PD and compared the effectiveness to different treatment modalities. CCH is a safe and effective injectable agent for all curvature directions in both acute and stable PD. It can be used in conjunction with multiple penile modeling techniques, in combination with sildenafil, and following a shortened administration protocol. Moderate to severe treatment-related adverse events occur at a rate of 9% and are typically managed conservatively. Intralesional injections of CCH are FDA approved as a nonsurgical treatment for men with PD. The IMPRESS trials were instrumental in demonstrating the efficacy and safety of CCH and provided a standard protocol for administration. Additional studies are required to optimize treatment protocols and use in combination therapies. Further investigation of patients with ventral curvatures, hourglass deformities, and those in acute phase is needed. Natale C, McLellan D, Yousif A, et al. Review of Intralesional Collagenase Clostridium Histolyticum Injection Therapy and Related Combination Therapies in the Treatment of Peyronie's Disease (an Update). Sex Med 2021;9:340-349.

Identifiants

pubmed: 32199788
pii: S2050-0521(20)30009-3
doi: 10.1016/j.sxmr.2020.01.005
pii:
doi:

Substances chimiques

Microbial Collagenase EC 3.4.24.3

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

340-349

Informations de copyright

Copyright © 2020 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Caleb Natale (C)

Department of Urology, Tulane University School of Medicine, New Orleans, USA.

David M McLellan (DM)

Department of Urology, Tulane University School of Medicine, New Orleans, USA.

Ayad Yousif (A)

Department of Urology, Tulane University School of Medicine, New Orleans, USA.

Wayne J G Hellstrom (WJG)

Department of Urology, Tulane University School of Medicine, New Orleans, USA. Electronic address: whellst@tulane.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH